Aurobindo Pharma has announced the incorporation of a new wholly owned subsidiary in Malaysia to expand its pharmaceutical products business in the country.

Called Aurobindo Pharma (Malaysia) SDN. BHD., it is incorporated through Helix Healthcare B.V., a wholly owned subsidiary of the company located in the Netherlands.  

The entity has been incorporated with an initial investment of RM 400,000 (approx. USD 100,000).

Headquartered in Hyderabad, Aurobindo Pharma is a leading manufacturer of active pharmaceutical ingredients (APIs) and formulation products, supported by strong R&D and global manufacturing capabilities. The company operates nine R&D centres (five in India and four in the US) and more than 29 commercial manufacturing and packaging facilities worldwide, with a combined capacity of over 50 billion formulation units and 19,000 plus MT APIs.

The company is present in over 150 markets, including the US, Europe, and key growth regions.